Prostate cancer recurrent
Not recruitingStudy Comparing Darolutamide and Androgen Deprivation Therapy to Placebo and Androgen Deprivation Therapy in Men with High-Risk Prostate Cancer Recurrence
Study Comparing Darolutamide and Androgen Deprivation Therapy to Placebo and Androgen Deprivation Therapy in Men with High-Risk Prostate Cancer Recurrence
- Disease:Prostate cancer recurrent
- Substances:DarolutamidePiflufolastat (18F)+1
Spain- Participants:18–64 years · 65+ years
- Substances:Darolutamide
- Sponsor:Bayer AG










